Danaher looks like a highly asymmetric buy after its selloff because it is likely to post revenue growth in 2027 and 2028. x.com 

Danaher is a cleaner way than Thermo Fisher to play an aging population. Its greater bioprocessing exposure ties it more directly to drug cost of goods. x.com 

Danaher's rebound looks like one to fade near $190 because bioprocessing, its bigger business, delivered disappointing sales and guidance. Weak trading in peers, with Repligen also lower, echoed that. A move from $165 to $190 in two days seems off; the initial flush may have been overdone, but it is hard to argue Danaher deserves to trade back at $200, where it entered earnings, after that bioprocessing commentary. x.com